非劣等性および同等性ランダム化試験の報告:CONSORT 2010声明の拡張
Gilda Piaggio1, Diana R Elbourne, Stuart J Pocock
1Statistika Consultoria, São Paulo, Brazil. gilda.piaggio@gmail.com
JAMA
|December 27, 2012
まとめ
この研究は,非劣等性および同等性試験の報告を改善するために,CONSORTのチェックリストを更新しています. 改善されたガイドラインは,読者がランダム化制御試験の結果の信頼性を評価するのに役立ちます.
科学分野:
- 臨床試験の方法論 臨床試験の方法論
- バイオ統計学 バイオ統計学
- 根拠に基づいた医学は,証拠に基づいた医療です.
背景:
- CONSORT Statement (Consolidated Standards of Reporting Trials) は,ランダム化統制試験 (RCT) の報告に関するガイドラインを提供します.
- 既存のCONSORTガイドラインは,主に優越性試験に焦点を当てており,2010年に最後に更新されました.
- 以前の非劣等性および同等性試験の勧告は2006年に発表された.
研究 の 目的:
- 非劣等性試験および同等性試験の報告のために特にCONSORTチェックリストの更新された拡張を提示します.
- これらの特定の試験設計の報告の明確性と完全性を高めるために.
- 読者が,非劣等性および同等性試験の信頼性と結論を評価するのを助けるために.
主な方法:
- 更新されたチェックリストは,抽象的な報告のための2010 CONSORT ステートメントと2008 CONSORT ステートメントに基づいています.
- 拡張は,非劣等性および同等性試験の設計に特有の項目を扱います.
- 修正されたチェックリストの項目の説明と例は示されています.
主要な成果:
- この記事では,非劣等性および同等性試験に合わせた精巧なCONSORTチェックリストを紹介しています.
- この更新されたチェックリストには,標準的な優越性試験報告を超えた具体的な考慮事項が含まれています.
- 目標は,公表された試験データの標準化と質の向上です.
結論:
- 更新されたCONSORTチェックリストの拡張は,非劣等性および同等性試験の報告を改善することを目的としています.
- よりよい報告は,試験結果の透明性と解釈性を高めます.
- このリソースは,研究者や読者が試験結果の妥当性を評価するのに役立ちます.
関連する概念動画
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...